CN Patent

CN120284999A — 用于治疗serpinc1相关病症的方法和组合物

Assigned to Genzyme Corp · Expires 2025-07-11 · 1y expired

What this patent protects

本发明涉及iRNA例如双链核糖核酸(dsRNA)、靶向Serpinc1基因的组合物和使用这样的iRNA例如dsRNA、组合物来抑制Serpinc1的表达和治疗具有Serpinc1相关疾病例如出血病症诸如血友病的受试者的方法。

USPTO Abstract

本发明涉及iRNA例如双链核糖核酸(dsRNA)、靶向Serpinc1基因的组合物和使用这样的iRNA例如dsRNA、组合物来抑制Serpinc1的表达和治疗具有Serpinc1相关疾病例如出血病症诸如血友病的受试者的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN120284999A
Jurisdiction: CN
Classification: —
Expires: 2025-07-11
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.